This Biotech Gift Keeps Giving
I can guarantee you one thing this holiday season…
The market has a few more surprises up its sleeve.
And that surprise could be very profitable for us.
Biotechs are Red-Hot Right Now
Back in November the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) quietly set up for an extended move higher.
The prevailing idea at the time was if these names could continue to move in the right direction to close out November, the biotech sector had a great shot at making an honest push toward new year-to-date highs and possibly even breaking out in a much bigger way.
And as you can see a few days later the IBB reaffirmed our suspicions a larger run was coming.
New highs are locked in and this could be just the beginning of a legendary runup in biotech.
That all said, we’re focused on one specific tiny stock that offers a lot more upside potential than the IBB.
The Biotech Gift that Keeps on Giving
Epizyme (NASDAQ: EPZM) is a leading epigenetics company tackling some of our biggest health problems, specifically targeting hard-to-treat cancers.
The company’s lead pipeline candidate is tazemetostat, which is designed for patients with relapsed or refractory non-Hodgkin lymphoma. Epizyme applied for an NDA for accelerated approval in July 2019. The FDA is expected to give its decision on Jan. 23, 2020.
Preliminary data look strong and I suspect much like Merck & Co.’s cancer drug Keytruda helped power MRK to huge gains this year, a successful FDA review for Epizyme could send this tiny biotech through the roof too.
This isn’t the first time I’ve suggested grabbing EPZM shares, either. Followers of my Tech Profits Daily letter could be up as much as 127% if they acted on my first alert back in October of 2018.
Gains could be harder to realize as shares bust through the $20. But I think EPZM could have some more room to grow moving forward.
I also suspect during the week before its priority review on Jan 23, we’ll see shares rip much higher.
And when revenue for this drug starts hitting EPZM’s books… Who knows how high this stock could run!
For Technology Profits Daily,
Chief Technology Expert, Technology Profits Daily